AI English summary of an SEC filing — figures as filed

Gilead said on Tuesday, July 17, 2024, that Chief Medical Officer Merdad V. Parsey, M.D., Ph.D., will leave the company. The company said no formal date has been set for his departure.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Jul 17, 2024Period of report Jul 17, 2024Summary published (UTC) Oct 26, 2026

Key points

AI summary

Gilead said on Tuesday, July 17, 2024, that Chief Medical Officer Merdad V. Parsey, M.D., Ph.D., will leave the company. The company said no formal date has been set for his departure.
Gilead said Dr. Parsey will remain in his role while the company looks for a successor and will then support the handover of his duties. The company said the transition is expected to run through Q1 2025 or another date mutually agreed.
Gilead said Dr. Parsey joined the company in November 2019 and has overseen its global clinical development and medical affairs organizations. The press release said he has served as Chief Medical Officer for the past 5 years.
Gilead said Chairman and Chief Executive Officer Daniel O'Day noted that the portfolio has more than doubled under Dr. Parsey's leadership. The company also said 54 clinical trials are ongoing across virology, oncology and inflammation.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Chief Medical Officer Departure Announced

Gilead said on Tuesday, July 17, 2024, that Chief Medical Officer Merdad V. Parsey, M.D., Ph.D., will leave the company. The company said no formal date has been set for his departure.

Source · Based on the filing body and exhibits

Role Continues and Handover While Successor Is Sought

Gilead said Dr. Parsey will remain in his role while the company looks for a successor and will then support the handover of his duties. The company said the transition is expected to run through Q1 2025 or another date mutually agreed.

Source · Based on the filing body and exhibits

Tenure and Responsibilities

Gilead said Dr. Parsey joined the company in November 2019 and has overseen its global clinical development and medical affairs organizations. The press release said he has served as Chief Medical Officer for the past 5 years.

Source · Based on the filing body and exhibits

Portfolio and Clinical Trial Status Cited by Gilead

Gilead said Chairman and Chief Executive Officer Daniel O'Day noted that the portfolio has more than doubled under Dr. Parsey's leadership. The company also said 54 clinical trials are ongoing across virology, oncology and inflammation.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.